Commentary: FDA nonapprovals stall life-saving therapies

Mark Thornton, a former medical officer in the FDA Office of Oncology Products, criticized the agency for failing to approve two "safe, promising" therapies designed to stimulate a patient's immune system to fight cancer. "While our lawmakers obsess over FDA 'safety reforms,' no one is holding this government agency accountable for its complicity in stalling therapies for life-threatening diseases," Thornton said.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT